Arcus Biosciences (NYSE:RCUS) Stock Price Down 5.8% - Should You Sell?

Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report)'s stock price traded down 5.8% on Tuesday . The stock traded as low as $9.95 and last traded at $9.90. 387,331 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 708,444 shares. The stock had previously closed at $10.50.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Bank of America lowered their price target on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a report on Wednesday, February 19th. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and raised their price target for the company from $18.00 to $24.00 in a report on Wednesday, February 26th. Finally, Morgan Stanley reduced their price objective on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $30.25.

Arcus Biosciences Price Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The stock has a market capitalization of $1.01 billion, a P/E ratio of -3.04 and a beta of 1.36. The firm has a 50-day moving average price of $12.90 and a 200 day moving average price of $15.25.

Remove Ads

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million. On average, analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Insider Buying and Selling

In related news, CFO Robert C. Goeltz II sold 3,594 shares of the firm's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now directly owns 60,138 shares in the company, valued at $902,070. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Yasunori Kaneko acquired 20,000 shares of the company's stock in a transaction on Thursday, February 27th. The stock was acquired at an average price of $10.06 per share, with a total value of $201,200.00. Following the acquisition, the director now owns 28,400 shares in the company, valued at approximately $285,704. This trade represents a 238.10 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arcus Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd purchased a new stake in Arcus Biosciences in the 4th quarter worth approximately $26,000. Point72 Hong Kong Ltd purchased a new stake in Arcus Biosciences in the 3rd quarter worth approximately $47,000. Lazard Asset Management LLC lifted its holdings in Arcus Biosciences by 3,321.3% in the 4th quarter. Lazard Asset Management LLC now owns 6,261 shares of the company's stock worth $93,000 after buying an additional 6,078 shares during the period. US Bancorp DE lifted its holdings in Arcus Biosciences by 2,432.0% in the 4th quarter. US Bancorp DE now owns 6,887 shares of the company's stock worth $103,000 after buying an additional 6,615 shares during the period. Finally, Quest Partners LLC lifted its holdings in Arcus Biosciences by 40,904.3% in the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company's stock worth $144,000 after buying an additional 9,408 shares during the period. Hedge funds and other institutional investors own 92.89% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.